Preoperative BChE serves as a prognostic marker in patients with resectable AEG after neoadjuvant chemotherapy.
Adenocarcinoma of the gastroesophageal junction (AEG)
Biomarker
Butyrylcholinesterase (BChE)
Oncologic treatment
Prognosis
Journal
Langenbeck's archives of surgery
ISSN: 1435-2451
Titre abrégé: Langenbecks Arch Surg
Pays: Germany
ID NLM: 9808285
Informations de publication
Date de publication:
06 Jun 2023
06 Jun 2023
Historique:
received:
03
03
2023
accepted:
12
05
2023
medline:
8
6
2023
pubmed:
7
6
2023
entrez:
6
6
2023
Statut:
epublish
Résumé
Diminished systemic serum butyrylcholinesterase (BChE), a biomarker for chronic inflammation, cachexia, and advanced tumor stage, has shown to play a prognostic role in various malignancies. The aim of this study was to investigate the prognostic value of pretherapeutic BChE levels in patients with resectable adenocarcinoma of the gastroesophageal junction (AEG), treated with or without neoadjuvant therapy. Data of a consecutive series of patients with resectable AEG at the Department for General Surgery, Medical University of Vienna, were analyzed. Preoperative serum BChE levels were correlated to clinic-pathological parameters as well as treatment response. The prognostic impact of serum BChE levels on disease-free (DFS) and overall survival (OS) was evaluated by univariate and multivariate cox regression analysis, and Kaplan-Meier curves used for illustration. A total of 319 patients were included in this study, with an overall mean (standard deviation, SD) pretreatment serum BChE level of 6.22 (± 1.91) IU/L. In univariate models, diminished preoperative serum BChE levels were significantly associated with shorter overall (OS, p < 0.003) and disease-free survival (DFS, p < 0.001) in patients who received neoadjuvant treatment and/or primary resection. In multivariated analysis, decreased BChE was significantly associated with shorter DFS (HR: 0.92, 95% CI: 0.84-1.00, p 0.049) and OS (HR: 0.92, 95% CI: 0.85-1.00, p < 0.49) in patients receiving neoadjuvant therapy. Backward regression identified the interaction between preoperative BChE and neoadjuvant chemotherapy as a predictive factor for DFS and OS. Diminished serum BChE serves as a strong, independent, and cost-effective prognostic biomarker for worse outcome in patients with resectable AEG who had received neoadjuvant chemotherapy.
Sections du résumé
BACKGROUND
BACKGROUND
Diminished systemic serum butyrylcholinesterase (BChE), a biomarker for chronic inflammation, cachexia, and advanced tumor stage, has shown to play a prognostic role in various malignancies. The aim of this study was to investigate the prognostic value of pretherapeutic BChE levels in patients with resectable adenocarcinoma of the gastroesophageal junction (AEG), treated with or without neoadjuvant therapy.
METHODS
METHODS
Data of a consecutive series of patients with resectable AEG at the Department for General Surgery, Medical University of Vienna, were analyzed. Preoperative serum BChE levels were correlated to clinic-pathological parameters as well as treatment response. The prognostic impact of serum BChE levels on disease-free (DFS) and overall survival (OS) was evaluated by univariate and multivariate cox regression analysis, and Kaplan-Meier curves used for illustration.
RESULTS
RESULTS
A total of 319 patients were included in this study, with an overall mean (standard deviation, SD) pretreatment serum BChE level of 6.22 (± 1.91) IU/L. In univariate models, diminished preoperative serum BChE levels were significantly associated with shorter overall (OS, p < 0.003) and disease-free survival (DFS, p < 0.001) in patients who received neoadjuvant treatment and/or primary resection. In multivariated analysis, decreased BChE was significantly associated with shorter DFS (HR: 0.92, 95% CI: 0.84-1.00, p 0.049) and OS (HR: 0.92, 95% CI: 0.85-1.00, p < 0.49) in patients receiving neoadjuvant therapy. Backward regression identified the interaction between preoperative BChE and neoadjuvant chemotherapy as a predictive factor for DFS and OS.
CONCLUSION
CONCLUSIONS
Diminished serum BChE serves as a strong, independent, and cost-effective prognostic biomarker for worse outcome in patients with resectable AEG who had received neoadjuvant chemotherapy.
Identifiants
pubmed: 37280384
doi: 10.1007/s00423-023-02938-w
pii: 10.1007/s00423-023-02938-w
pmc: PMC10244274
doi:
Substances chimiques
Butyrylcholinesterase
EC 3.1.1.8
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
227Informations de copyright
© 2023. The Author(s).
Références
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
BMC Cancer. 2016 Sep 06;16:722
pubmed: 27599460
World J Gastroenterol. 2013 May 14;19(18):2811-7
pubmed: 23687419
Oncotarget. 2016 Mar 22;7(12):15230-42
pubmed: 26885692
Nat Rev Cancer. 2014 Nov;14(11):754-62
pubmed: 25291291
Future Oncol. 2021 Jun;17(17):2257-2274
pubmed: 33739165
Ann Surg Oncol. 2007 Feb;14(2):381-9
pubmed: 17160496
Ann Surg. 2007 May;245(5):707-16
pubmed: 17457163
Cancer. 1994 Jun 1;73(11):2680-6
pubmed: 8194005
N Engl J Med. 2012 May 31;366(22):2074-84
pubmed: 22646630
World J Gastroenterol. 2005 Aug 7;11(29):4604-6
pubmed: 16052698
J Cancer Res Ther. 2008 Jan-Mar;4(1):21-5
pubmed: 18417898
Oncotarget. 2017 Feb 21;8(8):13400-13412
pubmed: 28077792
Oncotarget. 2017 Apr 11;8(15):24327-24336
pubmed: 28212582
Cancer Manag Res. 2021 Mar 12;13:2359-2370
pubmed: 33737833
Ann Surg Oncol. 2011 Oct;18(10):2757-63
pubmed: 21638093
Am J Surg. 2018 Jul;216(1):124-130
pubmed: 28802729
Ann Thorac Surg. 1994 Dec;58(6):1574-8; discussion 1578-9
pubmed: 7979718
Coll Antropol. 2000 Dec;24(2):373-80
pubmed: 11216405
Nat Rev Dis Primers. 2017 Jul 27;3:17048
pubmed: 28748917
Australas Med J. 2011;4(7):374-8
pubmed: 23393522
Cancer Epidemiol. 2016 Apr;41:88-95
pubmed: 26851752
Lancet Oncol. 2005 Sep;6(9):659-68
pubmed: 16129366
Ann Hepatol. 2012 May-Jun;11(3):356-63
pubmed: 22481455
J Inflamm Res. 2016 Nov 18;9:221-230
pubmed: 27920568
Br J Surg. 2021 Nov 11;108(11):1332-1340
pubmed: 34476473
Front Oncol. 2020 Feb 21;10:178
pubmed: 32154173
Oncotarget. 2018 Jan 8;9(6):6968-6976
pubmed: 29467943
Strahlenther Onkol. 2019 May;195(5):430-440
pubmed: 30737542
Lancet. 2001 Feb 17;357(9255):539-45
pubmed: 11229684
Curr Treat Options Oncol. 2016 May;17(5):21
pubmed: 27032643
Br J Surg. 1998 Nov;85(11):1457-9
pubmed: 9823902
Lancet Oncol. 2015 Sep;16(9):1090-1098
pubmed: 26254683
Acta Biomed. 2021 Nov 03;92(5):e2021284
pubmed: 34738601
Eur Surg. 2021;53(6):287-293
pubmed: 34868284
Eur J Surg Oncol. 2017 Feb;43(2):478-484
pubmed: 28024944
Int Urol Nephrol. 2018 Sep;50(9):1713-1720
pubmed: 30128921